Alpine Immune Sciences
$16.52
13
+$0.28+1.72% Thursday 21:00
Statistics
Day High
16.88
Day Low
15.92
52W High
16.88
52W Low
5.81
Volume
319,380
Avg. Volume
675,146
Mkt Cap
959.78M
P/E Ratio
-13.54
Dividend Yield
-
Dividend
-
Upcoming
Earnings
14NovConfirmed
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
-0.6
-0.43
-0.27
-0.1
Expected EPS
-0.33
Actual EPS
-0.24
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ALPN. It's not an investment recommendation.
Analyst Ratings
22.5$Average Price Target
The highest estimate is $30.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%
About
Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Show more...
CEO
Charles Scoggin
Employees
85
Country
US
ISIN
US02083G1004
WKN
000A2DU89